13 May, 2024May Health Raises $25 Million in Series B Funding to Advance Development for Ovarian Rebalancing Therapy
6 May, 2024Mediar Advances First-in-Class Fibrosis Portfolio to the Clinic with First Cohort Dosing in Phase 1 trial of MTX-463 and Establishes Clinical Advisory Board
6 May, 2024Calliditas announces positive topline results of Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib
2 May, 2024Amolyt Pharma Granted FDA Fast Track Designation for Eneboparatide for the Treatment of Hypoparathyroidism